Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Wednesday

Alpha Tau Medical (NASDAQ:DRTS) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Alpha Tau Medical Trading Down 7.3%

NASDAQ DRTS opened at $7.07 on Wednesday. The firm has a market capitalization of $599.68 million, a price-to-earnings ratio of -13.60 and a beta of 1.02. The firm’s 50 day simple moving average is $6.80 and its 200 day simple moving average is $4.97. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical during the third quarter valued at $62,000. Bank of America Corp DE increased its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN raised its position in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after purchasing an additional 17,500 shares during the last quarter. Millennium Management LLC acquired a new position in Alpha Tau Medical during the 3rd quarter worth about $170,000. Finally, Mariner LLC lifted its holdings in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after buying an additional 80,129 shares during the period. 2.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DRTS has been the subject of several recent analyst reports. Citigroup cut their target price on Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, December 10th. HC Wainwright restated a “buy” rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.